Skip to main content

Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ:TLSA). He gives his take on what the market can expect from the business this year, saying that it is now "moving forward quite nicely."

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.